Clinical Trial

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-04-14; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT06940427
Lead Sponsor University of Wisconsin, Madison
Conditions Fibrosis Lung
Enrollment 50 participants
Start Date 2025-11-19
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-11